Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 NODAGA-JR11 in metastatic neuroendocrine tumors
NCT04897542Phase 1Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-satoreotide trizoxetan in Neuroendocrine Neoplasm (NEN), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Standardized Uptake Value. Status: unknown.
02
Drugs
68Ga-satoreotide trizoxetan
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04897542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897542.